$6.06-4.3%Nov 13 close
The latest quarter (ended September 30, 2026) is from CapsoVision’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once CapsoVision files it.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $3.6M | $3.5M | +0.85% |
| Free Cash Flow | -$7.1M | -$5.7M | -24.41% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video review. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from CapsoVision’s earnings press release (an Item 2.02 8-K) filed November 12, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.
CapsoVision, Inc reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Just reported
From CapsoVision, Inc's results release of November 12, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
$3.6M
+0.8% y/y
-2.1% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.